- Home
- VTEX vs ARVN Comparison
VTEX vs ARVN Comparison
Compare VTEX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- ARVN
- Stock Information
- Founded
- VTEX 1999
- ARVN 2015
- Country
- VTEX Cayman Islands
- ARVN United States
- Employees
- VTEX N/A
- ARVN N/A
- Industry
- VTEX Computer Software: Prepackaged Software
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- ARVN Health Care
- Exchange
- VTEX Nasdaq
- ARVN Nasdaq
- Market Cap
- VTEX 742.4M
- ARVN 680.6M
- IPO Year
- VTEX 2021
- ARVN 2018
- Fundamental
- Price
- VTEX $4.41
- ARVN $9.61
- Analyst Decision
- VTEX Strong Buy
- ARVN Buy
- Analyst Count
- VTEX 4
- ARVN 23
- Target Price
- VTEX $7.63
- ARVN $17.70
- AVG Volume (30 Days)
- VTEX 1.1M
- ARVN 2.3M
- Earning Date
- VTEX 11-04-2025
- ARVN 10-29-2025
- Dividend Yield
- VTEX N/A
- ARVN N/A
- EPS Growth
- VTEX 48.79
- ARVN N/A
- EPS
- VTEX 0.05
- ARVN N/A
- Revenue
- VTEX $230,497,000.00
- ARVN $372,800,000.00
- Revenue This Year
- VTEX $10.08
- ARVN $1.61
- Revenue Next Year
- VTEX $14.18
- ARVN N/A
- P/E Ratio
- VTEX $84.58
- ARVN N/A
- Revenue Growth
- VTEX 4.53
- ARVN 299.57
- 52 Week Low
- VTEX $3.92
- ARVN $5.90
- 52 Week High
- VTEX $7.56
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- VTEX 49.73
- ARVN 81.74
- Support Level
- VTEX $4.27
- ARVN $7.38
- Resistance Level
- VTEX $4.52
- ARVN $8.11
- Average True Range (ATR)
- VTEX 0.15
- ARVN 0.45
- MACD
- VTEX 0.03
- ARVN 0.19
- Stochastic Oscillator
- VTEX 43.97
- ARVN 93.20
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.